Part No: AN093.v2Issued year: 2014File size: 0.67mbFile type: pdf
We demonstrate the capability of the Biotage® Initiator+ Alstra™ microwave peptide synthesizer to fully automate the on-resin synthesis of cyclic peptides with examples showing disulfide bridge formation and side-chain to side-chain cyclization respectively.
Part No: P175Issued year: 2018File size: 2.14mbFile type: pdf
This poster presents a method for detection of approximately 100 drugs and metabolites in urine using mixed-mode polymeric cation exchange solid phase extraction (SPE).
Four different glucuronidase enzymes and several incubation times and temperatures were evaluated to determine optimum hydrolysis conditions for seven commonly detected glucuronide metabolites. Samples were subjected to offline hydrolysis and SPE (EVOLUTE® EXPRESS CX, Biotage, Charlotte, NC) and results compared to an SPE plate that incorporates in-well hydrolysis (EVOLUTE HYDRO CX, Biotage).
MSACL 2018, Palm Springs, CA
Part No: PPS479Issued year: 2018File size: 0.12mbFile type: pdf
Based on our customers’ needs, Biotage creates tailor-made
assurance plans consisting of a combination of products:
»» Technical assistance
»» Periodic Performance Maintenance visits
»» Spare parts supply and discount programs
»» Trainings designed to fit your demands and requirements
This brochure presents the extensive range of instrumentation for flash purification from Biotage. To complement these products Biotage also offers a complete range of flash consumables, including columns in a variety of sizes packed with irregular and spherical silica, making Biotage your one-stop partner for your flash purification needs.
Keywords: Isolera™ Dalton, Isolera™ Spektra, 10 Isolera™ Spektra One and Four, Isolera™ Spektra LS (Large Scale), Isolera™ Prime, Isolera™ ELSD-1080, Biotage® Flash 75/150, Biotage® Flash 400
Part No: BiotHR1Issued year: 2017File size: 0.15mbFile type: pdf
This statement sets out Biotage’s actions to understand all potential modern slavery risks related to its business and to put in place steps that aim at reducing the risk of slavery or human trafficking occurring within in its own business and its supply chains. This statement relates to actions and activities during the financial year 1 Jan 2016 to 31 December 2016.